FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309702982> ?p ?o ?g. }

• W4309702982 endingPage "537" @default.
• W4309702982 startingPage "528" @default.
• W4309702982 abstract "Thymic epithelial tumors (TETs) are rare thoracic malignancies with no standard second-line treatment. Tumor angiogenesis is closely associated with the pathogenesis and invasiveness of TETs. Anlotinib is a small-molecule multitarget tyrosine kinase inhibitor (TKI) which inhibits tumor angiogenesis and tumor cell proliferation. Published studies have demonstrated the promising clinical effect of multitarget TKIs sunitinib and lenvatinib in previously treated TETs. However, TKIs have a high incidence of adverse events (AEs).In this study, we investigated the clinical efficacy and safety of anlotinib in previously treated TET patients.We collected clinical data of 22 patients from Shandong Cancer Hospital and Institute between October 2018 and March 2022. These patients were diagnosed with advanced TETs and received at least the first-line (1st-line) treatment. We analyzed the clinical effects between anlotinib monotherapy and anlotinib combination therapy in the second-line (2nd-line) or anlotinib treatment in different lines.These 22 patients included 18 cases of thymic carcinoma (TC) and 4 cases of thymoma (T). 68.2% of patients were males, and the median age was 53 years. Fourteen patients (63.6%) received anlotinib monotherapy and 8 patients (36.4%) received anlotinib combination therapy. The objective response rate (ORR) was 9.1% in the overall patients. The median progression-free survival (PFS) in the overall population was 12 months (14 months for T and 9 months for TC), and the median overall survival (OS) was 24 months (survival was not reached for T and was 24 months for TC). The incidence of AEs was 50%, most of them were grades I and II, and the incidence of grades III and IV AEs was 9%.This is the first study reporting the clinical effect of anlotinib in previously treated TETs patients. The survival data indicate that the efficacy of anlotinib is superior to sunitinib and lenvatinib. Our results suggest that anlotinib is a promising treatment option for previously treated TET patients and its toxicity is tolerable. More research and patents are needed in the future to explore better options for the diagnosis and treatment of TETs." @default.
• W4309702982 created "2022-11-29" @default.
• W4309702982 creator A5001844202 @default.
• W4309702982 creator A5023964547 @default.
• W4309702982 creator A5024090635 @default.
• W4309702982 creator A5043296622 @default.
• W4309702982 creator A5067274947 @default.
• W4309702982 creator A5069444453 @default.
• W4309702982 creator A5072636530 @default.
• W4309702982 date "2023-11-01" @default.
• W4309702982 modified "2023-10-15" @default.
• W4309702982 title "The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis" @default.
• W4309702982 cites W1767875808 @default.
• W4309702982 cites W1875240237 @default.
• W4309702982 cites W1980536918 @default.
• W4309702982 cites W2047139031 @default.
• W4309702982 cites W2059654711 @default.
• W4309702982 cites W2072689130 @default.
• W4309702982 cites W2168558240 @default.
• W4309702982 cites W2287570444 @default.
• W4309702982 cites W2346237485 @default.
• W4309702982 cites W2474181961 @default.
• W4309702982 cites W2613990243 @default.
• W4309702982 cites W2757603257 @default.
• W4309702982 cites W2784751095 @default.
• W4309702982 cites W2791667474 @default.
• W4309702982 cites W2808003286 @default.
• W4309702982 cites W2885496181 @default.
• W4309702982 cites W2888307903 @default.
• W4309702982 cites W2903468527 @default.
• W4309702982 cites W2938876444 @default.
• W4309702982 cites W2963572064 @default.
• W4309702982 cites W2981698704 @default.
• W4309702982 cites W2991155446 @default.
• W4309702982 cites W3022554601 @default.
• W4309702982 cites W3032195772 @default.
• W4309702982 cites W3034160707 @default.
• W4309702982 cites W3089347876 @default.
• W4309702982 cites W3109934647 @default.
• W4309702982 cites W3150836655 @default.
• W4309702982 cites W3185808632 @default.
• W4309702982 cites W4225113872 @default.
• W4309702982 cites W4237668569 @default.
• W4309702982 cites W4246097753 @default.
• W4309702982 cites W864587925 @default.
• W4309702982 doi "https://doi.org/10.2174/1574892818666221122114753" @default.
• W4309702982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36415100" @default.
• W4309702982 hasPublicationYear "2023" @default.
• W4309702982 type Work @default.
• W4309702982 citedByCount "0" @default.
• W4309702982 crossrefType "journal-article" @default.
• W4309702982 hasAuthorship W4309702982A5001844202 @default.
• W4309702982 hasAuthorship W4309702982A5023964547 @default.
• W4309702982 hasAuthorship W4309702982A5024090635 @default.
• W4309702982 hasAuthorship W4309702982A5043296622 @default.
• W4309702982 hasAuthorship W4309702982A5067274947 @default.
• W4309702982 hasAuthorship W4309702982A5069444453 @default.
• W4309702982 hasAuthorship W4309702982A5072636530 @default.
• W4309702982 hasBestOaLocation W43097029821 @default.
• W4309702982 hasConcept C121608353 @default.
• W4309702982 hasConcept C126322002 @default.
• W4309702982 hasConcept C143998085 @default.
• W4309702982 hasConcept C197934379 @default.
• W4309702982 hasConcept C2776349617 @default.
• W4309702982 hasConcept C2776694085 @default.
• W4309702982 hasConcept C2776999253 @default.
• W4309702982 hasConcept C2778820342 @default.
• W4309702982 hasConcept C2779490328 @default.
• W4309702982 hasConcept C2780739268 @default.
• W4309702982 hasConcept C2781230642 @default.
• W4309702982 hasConcept C71924100 @default.
• W4309702982 hasConceptScore W4309702982C121608353 @default.
• W4309702982 hasConceptScore W4309702982C126322002 @default.
• W4309702982 hasConceptScore W4309702982C143998085 @default.
• W4309702982 hasConceptScore W4309702982C197934379 @default.
• W4309702982 hasConceptScore W4309702982C2776349617 @default.
• W4309702982 hasConceptScore W4309702982C2776694085 @default.
• W4309702982 hasConceptScore W4309702982C2776999253 @default.
• W4309702982 hasConceptScore W4309702982C2778820342 @default.
• W4309702982 hasConceptScore W4309702982C2779490328 @default.
• W4309702982 hasConceptScore W4309702982C2780739268 @default.
• W4309702982 hasConceptScore W4309702982C2781230642 @default.
• W4309702982 hasConceptScore W4309702982C71924100 @default.
• W4309702982 hasFunder F4320321001 @default.
• W4309702982 hasFunder F4320323137 @default.
• W4309702982 hasFunder F4320326042 @default.
• W4309702982 hasFunder F4320328999 @default.
• W4309702982 hasFunder F4320333596 @default.
• W4309702982 hasFunder F4320335777 @default.
• W4309702982 hasIssue "4" @default.
• W4309702982 hasLocation W43097029821 @default.
• W4309702982 hasLocation W43097029822 @default.
• W4309702982 hasLocation W43097029823 @default.
• W4309702982 hasOpenAccess W4309702982 @default.
• W4309702982 hasPrimaryLocation W43097029821 @default.
• W4309702982 hasRelatedWork W1990823594 @default.
• W4309702982 hasRelatedWork W2080726748 @default.
• W4309702982 hasRelatedWork W2113599696 @default.

• next